08:00 Thu 16 Jul 2020
Shield Therapeutics - PT20 paper publication
("Shield" or the "Group" or the "Company")
PT20 paper publication
Demonstrates statistically significant and dose-dependent reduction in serum phosphate concentration
PT20 is a novel iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia (when there is too much phosphorus present in the blood) related to dialysis or non-dialysis dependent chronic kidney disease (CKD). The publication Nephrology Dialysis Transplantation has published a paper entitled "Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease." The study, which was funded by Shield, was a pivotal study to support marketing authorisation submissions and was a double-blind, parallel-group, placebo-controlled, dose-ranging study in which the efficacy and safety of 28 days of oral PT20 treatment were evaluated in patients with dialysis-dependent CKD. Participants were randomly assigned to receive PT20 or placebo three times daily. The study demonstrated that PT20 treatment for 28 days resulted in a statistically significant and dose-dependent reduction in serum phosphate concentration and was generally well tolerated.
The paper is available online here:
Shield has agreed with the
For further information please contact:
|
|
Tim Watts, CEO |
+44 (0)20 7186 8500 |
Karen Chandler Smith, Investor Relations |
|
Nominated Adviser and Joint Broker |
|
|
|
James Steel/Dr Christopher Golden |
+44 (0)20 7418 8900 |
Joint Broker finnCap Ltd Geoff Nash/Matt Radley/Alice Lane |
+44 (0)20 7220 0500 |
|
|
Financial PR & IR Advisor |
|
Walbrook PR |
+44 (0)20 7933 8780 or shield@walbrookpr.com |
Paul McManus/Lianne Cawthorne |
+44 (0)7980 541 893 / +44 (0)7584 391 303 |
About
Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States,
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE